SCHEMBL3154263

SCHEMBL3154263

O=C(NCc1ccc(C(F)(F)F)c(Cl)c1)c1ccc(S(=O)(=O)Nc2ncc(Cl)s2)cc1

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN3A Q9NY46 9/20 0.86
MAPT P10636 4/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
HTT P42858 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA7 P43166 1/20 0.45
CA9 Q16790 1/20 0.45
LMNA P02545 1/20 0.45
SCN9A Q15858 3/20 0.44
SCN1A P35498 2/20 0.44
SCN5A Q14524 2/20 0.44
SCN2A Q99250 2/20 0.44
SCN8A Q9UQD0 2/20 0.44
SCN10A Q9Y5Y9 2/20 0.44
KCNH2 Q12809 1/20 0.44
NAMPT P43490 3/20 0.42
WDR5 P61964 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3169304 0.92 SCN3A (0.82) SCN3AMAPTMEN1KMT2AHTT
SCHEMBL3127375 0.92 SCN3A (0.73) SCN3AMAPTMEN1KMT2AHTT
SCHEMBL3165532 0.90 SCN3A (0.85) SCN3AMAPTMEN1KMT2AHTT
SCHEMBL3173981 0.90 SCN3A (0.71) SCN3AMAPTMEN1KMT2AHTT
SCHEMBL3158744 0.89 SCN3A (0.79) SCN3AMAPTMEN1KMT2AHTT
SCHEMBL3159810 0.88 SCN3A (0.75) SCN3AMAPTMEN1KMT2AHTT
SCHEMBL3260132 0.88 SCN3A (0.78) SCN3AMAPTMEN1KMT2AHTT
SCHEMBL3168790 0.86 SCN3A (0.78) SCN3AMAPTMEN1KMT2AHTT
SCHEMBL3164340 0.85 SCN3A (0.75) SCN3AMAPTMEN1KMT2AHTT
SCHEMBL3161091 0.85 SCN3A (0.64) SCN3AMAPTMEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8741934-B2 Inhibitors of ion channels PFIZER LIMITED (GB) 2014-06-03 US disclosed
US-20130072471-A1 Inhibitors of Ion Channels MARRON BRIAN EDWARD (US) 2013-03-21 US disclosed
US-8357711-B2 Heterocyclic sulfonamides as inhibitors of ion channels PFIZER LIMITED (GB) 2013-01-22 US disclosed
EP-1995241-B1 Inhibitors of ion channels ICAGEN INC (US) 2010-03-17 EP disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US disclosed
EP-1995241-A1 Inhibitors of ion channels ICAgen, Incorporated (US) 2008-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072471-A1 Inhibitors of Ion Channels TRPV1, TRPV5, TRPA1 SCN3A 13/4885MAPT 2938/4885MEN1 4729/4885
US-20090143358-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 SCN3A 13/4885MAPT 2938/4885MEN1 4729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.